Cargando…

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

Streptococcus pneumoniae is the main bacterial cause of respiratory infections in children and the elderly worldwide. Serotype replacement is a frequent phenomenon after the introduction of conjugated vaccines, with emerging serotypes 22F and 33F as frequent non-PCV13 serotypes in children and adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Sempere, Julio, de Miguel, Sara, González-Camacho, Fernando, Yuste, José, Domenech, Mirian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056674/
https://www.ncbi.nlm.nih.gov/pubmed/32174903
http://dx.doi.org/10.3389/fmicb.2020.00309
_version_ 1783503514732855296
author Sempere, Julio
de Miguel, Sara
González-Camacho, Fernando
Yuste, José
Domenech, Mirian
author_facet Sempere, Julio
de Miguel, Sara
González-Camacho, Fernando
Yuste, José
Domenech, Mirian
author_sort Sempere, Julio
collection PubMed
description Streptococcus pneumoniae is the main bacterial cause of respiratory infections in children and the elderly worldwide. Serotype replacement is a frequent phenomenon after the introduction of conjugated vaccines, with emerging serotypes 22F and 33F as frequent non-PCV13 serotypes in children and adults in North America and other countries. Characterization of mechanisms involved in evasion of the host immune response by these serotypes is of great importance in public health because they are included in the future conjugated vaccines PCV15 and PCV20. One of the main strategies of S. pneumoniae to persistently colonize and causes infection is biofilm formation. In this study, we have evaluated the influence of capsule polysaccharide in biofilm formation and immune evasion by using clinical isolates from different sources and isogenic strains with capsules from prevalent serotypes. Since the introduction of PCV13 in Spain in the year 2010, isolates of serotypes 22F and 33F are rising among risk populations. The predominant circulating genotypes are ST433(22F) and ST717(33F), being CC433 in 22F and CC717 in 33F the main clonal complexes in Spain. The use of clinical isolates of different origin, demonstrated that pediatric isolates of serotypes 22F and 33F formed better biofilms than adult isolates and this was statistically significant. This phenotype was greater in clinical isolates from blood origin compared to those from cerebrospinal fluid, pleural fluid and otitis. Opsonophagocytosis assays showed that serotype 22F and 33F were recognized by the PSGL-1 receptor on leukocytes, although serotype 22F, was more resistant than serotype 33F to phagocytosis killing and more lethal in a mouse sepsis model. Overall, the emergence of additional PCV15 serotypes, especially 22F, could be associated to an enhanced ability to divert the host immune response that markedly increased in a biofilm state. Our findings demonstrate that pediatric isolates of 22F and 33F, that form better biofilm than isolates from adults, could have an advantage to colonize the nasopharynx of children and therefore, be important in carriage and subsequent dissemination to the elderly. The increased ability of serotype 22F to avoid the host immune response, might explain the emergence of this serotype in the last years.
format Online
Article
Text
id pubmed-7056674
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70566742020-03-13 Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain Sempere, Julio de Miguel, Sara González-Camacho, Fernando Yuste, José Domenech, Mirian Front Microbiol Microbiology Streptococcus pneumoniae is the main bacterial cause of respiratory infections in children and the elderly worldwide. Serotype replacement is a frequent phenomenon after the introduction of conjugated vaccines, with emerging serotypes 22F and 33F as frequent non-PCV13 serotypes in children and adults in North America and other countries. Characterization of mechanisms involved in evasion of the host immune response by these serotypes is of great importance in public health because they are included in the future conjugated vaccines PCV15 and PCV20. One of the main strategies of S. pneumoniae to persistently colonize and causes infection is biofilm formation. In this study, we have evaluated the influence of capsule polysaccharide in biofilm formation and immune evasion by using clinical isolates from different sources and isogenic strains with capsules from prevalent serotypes. Since the introduction of PCV13 in Spain in the year 2010, isolates of serotypes 22F and 33F are rising among risk populations. The predominant circulating genotypes are ST433(22F) and ST717(33F), being CC433 in 22F and CC717 in 33F the main clonal complexes in Spain. The use of clinical isolates of different origin, demonstrated that pediatric isolates of serotypes 22F and 33F formed better biofilms than adult isolates and this was statistically significant. This phenotype was greater in clinical isolates from blood origin compared to those from cerebrospinal fluid, pleural fluid and otitis. Opsonophagocytosis assays showed that serotype 22F and 33F were recognized by the PSGL-1 receptor on leukocytes, although serotype 22F, was more resistant than serotype 33F to phagocytosis killing and more lethal in a mouse sepsis model. Overall, the emergence of additional PCV15 serotypes, especially 22F, could be associated to an enhanced ability to divert the host immune response that markedly increased in a biofilm state. Our findings demonstrate that pediatric isolates of 22F and 33F, that form better biofilm than isolates from adults, could have an advantage to colonize the nasopharynx of children and therefore, be important in carriage and subsequent dissemination to the elderly. The increased ability of serotype 22F to avoid the host immune response, might explain the emergence of this serotype in the last years. Frontiers Media S.A. 2020-02-27 /pmc/articles/PMC7056674/ /pubmed/32174903 http://dx.doi.org/10.3389/fmicb.2020.00309 Text en Copyright © 2020 Sempere, de Miguel, González-Camacho, Yuste and Domenech. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Sempere, Julio
de Miguel, Sara
González-Camacho, Fernando
Yuste, José
Domenech, Mirian
Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title_full Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title_fullStr Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title_full_unstemmed Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title_short Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain
title_sort clinical relevance and molecular pathogenesis of the emerging serotypes 22f and 33f of streptococcus pneumoniae in spain
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056674/
https://www.ncbi.nlm.nih.gov/pubmed/32174903
http://dx.doi.org/10.3389/fmicb.2020.00309
work_keys_str_mv AT semperejulio clinicalrelevanceandmolecularpathogenesisoftheemergingserotypes22fand33fofstreptococcuspneumoniaeinspain
AT demiguelsara clinicalrelevanceandmolecularpathogenesisoftheemergingserotypes22fand33fofstreptococcuspneumoniaeinspain
AT gonzalezcamachofernando clinicalrelevanceandmolecularpathogenesisoftheemergingserotypes22fand33fofstreptococcuspneumoniaeinspain
AT yustejose clinicalrelevanceandmolecularpathogenesisoftheemergingserotypes22fand33fofstreptococcuspneumoniaeinspain
AT domenechmirian clinicalrelevanceandmolecularpathogenesisoftheemergingserotypes22fand33fofstreptococcuspneumoniaeinspain